Anuh Pharma has received board approval for a ₹75 crore loan aimed at expanding its manufacturing assets and increasing production capacity. The decision was taken during the Board of Directors meeting held on October 13, 2026.

Board approval and loan details

The board approved two related items: investment in manufacturing assets for expansion and the proposal to avail a loan of up to ₹75 crore specifically for the purchase of these assets. The loan is intended to fund the expansion of the company's production capacity. This action is subject to the finalisation of terms and conditions and the receipt of applicable approvals, wherever required.

Regulatory disclosure

Anuh Pharma stated that requisite details and annexures, to the extent applicable under the SEBI (LODR) Regulations, 2015, shall be disclosed based on the actual details of the transaction. No further specifics regarding the timeline, facility location, or product scope were disclosed at this stage. The meeting commenced at 3:30 pm and concluded at 4:35 pm.

Anuh Pharma received a demand order of ₹9.93 lakh from the Income Tax Department on September 18, 2026. The notice pertains to the assessment year 2018-19 and cites disallowances of certain deductions claimed under the Income Tax Act, 1961.

The order was issued by the Assessment Unit under Section 156 of the Income Tax Act. The company disclosed the development pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Disclosure Details

Anuh Pharma stated it is filing an appeal before the Commissioner of Income Tax within prescribed timelines. Management believes it has adequate factual and legal grounds to substantiate its position.

Operational Impact

The company asserted that the tax demand has no impact on its financial operations or other activities. No provision was mentioned in the disclosure regarding the potential liability.

What the Numbers Show

The demand amount of ₹9.93 lakh is relatively modest for a listed pharmaceutical entity. The specific reference to "disallowances of deductions" suggests a dispute over expense eligibility rather than a fundamental reassessment of taxable income base. The company's decision to appeal immediately indicates confidence in its documentation, avoiding potential interest accruals associated with delayed payments.